Hair and Scalp

Finasteride 1 mg vs 5 mg: Why the Indication and Strength Matter

Understand why hair-loss and prostate prescriptions use different strengths, how to judge a response over time, and which safety changes need action.

By Global Medicines ExportPublished: Updated: Educational article

Reference comparison

Finasteride strength and treatment goal

Two UK oral reference products are compared below. Use the current leaflet for the exact presentation prescribed.

Strength, indication and follow-up in the UK references

Tablet strengthReference indicationMain follow-up focus
1 mgMale pattern hair loss in menHair stabilisation, response and tolerability
5 mgBPH in men with an enlarged prostateUrinary symptoms and prostate assessment

The same ingredient serves two different treatment goals

Finasteride reduces the activity of an enzyme involved in producing dihydrotestosterone, usually shortened to DHT. DHT influences the prostate and susceptible scalp hair follicles. A medicine can therefore affect both tissues while its prescribed use, strength and follow-up depend on the diagnosis.

The UK 5 mg reference treats benign prostatic hyperplasia, or BPH. This means non-cancerous prostate enlargement, which can affect urine flow. Hesitancy, frequent night-time urination and incomplete emptying can also have other causes. Treatment begins with an assessment of those symptoms. The UK 1 mg reference instead concerns male pattern hair loss. The strength printed on a pack records the ingredient amount in each tablet.

How lowering DHT relates to male pattern hair loss

In androgenetic alopecia, susceptible follicles gradually produce smaller, finer hairs. Finasteride inhibits type II 5-alpha reductase, reducing conversion of testosterone to DHT. Lower DHT exposure can slow the process affecting these follicles. A change in hormone activity happens before a visible change in scalp coverage, because hair growth takes time.

The US PROPECIA studies described men aged 18 to 41 with mild to moderate androgenetic alopecia. Investigators assessed hair counts, photographs and patient impressions. Those results explain the evidence for that reference product and population. They do not predict an identical outcome for every age, hair-loss pattern or different branded presentation. Keeping the study context alongside a result makes it easier to understand what the evidence can answer.

What a worthwhile hair response can look like

Hair stabilisation means that further visible thinning has slowed or stopped. Regrowth means an improvement from the starting appearance or measured hair count. Both appeared as separate outcomes in the US reference studies. Maintaining coverage can matter even when a person does not see a dramatic change in a photograph.

A review should compare the same scalp area with its earlier appearance. Similar lighting, hair length and camera angle make photographs more interpretable. The starting pattern, treatment duration and any other scalp problem belong in that comparison. A single good or bad hair day gives little information about a months-long trend. Continued thinning, a new pattern or troublesome symptoms provides a reason to reassess the diagnosis and plan.

How long benefit takes and what happens after stopping

The UK 1 mg product information generally allows three to six months before evidence of stabilisation can be expected. This describes an assessment window, with continued review of effectiveness and tolerability. It gives no basis for judging treatment after only a few tablets. The same information states that increasing the dose has not been shown to increase hair-loss efficacy.

For the UK hair-loss reference, benefit needs continued treatment. After stopping, the label describes beneficial effects beginning to reverse by six months and returning to baseline within nine to twelve months. A decision to stop should also account for the reason, especially a safety concern. For BPH, the UK 5 mg reference says at least six months may be needed to assess benefit. Its review focuses on urinary symptoms and prostate care.

Daily use, a missed tablet and duplicate ingredients

NHS guidance describes swallowing tablets whole with water, taking them consistently, and use with or without food. Check the directions for the actual supplied pack. The UK 5 mg reference specifically says its tablets should not be divided or crushed. A different-strength pack should be checked against the prescription before use.

For a missed tablet, the UK 1 mg patient leaflet says to avoid doubling the dose. NHS guidance also distinguishes remembering a dose from being nearly due for the next one. The exact leaflet can resolve that timing question. Keep a complete medicine list, particularly another finasteride product or dutasteride, so a prescriber can identify duplicate treatment before it is taken.

The current mood warnings differ by prescribed strength

The MHRA update published on 11 May 2026 reinforces reports of depression, suicidal thoughts and sexual dysfunction. Before treatment, a history of depression or suicidal thoughts belongs in the prescribing review. During treatment, new symptoms need attention. The EMA review confirmed suicidal thoughts as a side effect of finasteride tablets, with a frequency that could not be estimated from available evidence.

The MHRA advises people taking finasteride 1 mg to stop immediately and contact their healthcare professional as soon as possible if depression or suicidal thoughts develop. For 5 mg, it advises seeking medical advice as soon as possible. Urgent concern for personal safety requires immediate medical help. The patient alert card and leaflet explain the action for the prescribed product.

Sexual effects and other changes worth reporting

Reported sexual effects include reduced desire, erection difficulties and ejaculation problems. MHRA advice covers reports that sexual dysfunction continued after treatment stopped. Its 2026 update also highlights that sexual-function problems may contribute to mood changes. These symptoms warrant a review even when there has been no change in mood.

The review can consider when symptoms began, their effect on daily life and other possible contributors, including existing health conditions and other medicines. Report breast lumps, nipple discharge or new breast changes promptly. Swelling of the face, tongue or throat, or difficulty breathing, needs urgent assessment for a possible serious allergic reaction. The supplied leaflet contains the full adverse-effect information.

Pregnancy handling and PSA results need specific context

People who are pregnant or could be pregnant should avoid handling broken or crushed finasteride tablets. The UK leaflet explains a potential risk to male fetal development if the ingredient is absorbed. The coating limits contact during normal handling of intact tablets. If exposure occurs, obtain prompt advice and identify the product involved.

Finasteride can lower prostate-specific antigen, or PSA. This matters when a clinician interprets a prostate test. The UK 5 mg reference describes a substantial reduction in men treated for BPH and gives instructions for clinical interpretation after sustained treatment. Tell the team which strength you take and when it began. A lower result during treatment cannot by itself exclude a prostate problem, and patients should not make their own numerical correction.

Check whether another cause contributes to hair loss

A scalp examination and a history of the onset can distinguish gradual pattern thinning from widespread shedding, patches, breakage or scalp inflammation. Dermatology assessment can also consider illness, nutritional deficiency, hormonal conditions or infection. More than one cause can exist at the same time, which is why a new change deserves its own explanation.

Our guide Hair Shedding After Weight Loss explains the timing and assessment of a different shedding pattern. Does Biotin Help Hair Loss? Evidence and Blood-Test Interference explains another common follow-up question. Bring supplement labels to an assessment along with the medicine list. Testing should follow the suspected cause, and a supplement choice should follow the findings rather than the appearance of the marketing label.

Plan follow-up and identify the exact product

A practical follow-up record contains the treatment goal, starting date, exact strength, changes in symptoms and any adverse effects. Hair reviews can compare photographs and the trend in coverage. BPH reviews can assess urinary symptoms and any required prostate investigations. Agree on the review date and the route for reporting a new problem when the prescription starts.

The GME catalogue has separate listings for Finasteride 1 mg Tablets and Finasteride 5 mg Tablets. Match the prescription to the ingredient, strength, manufacturer and pack leaflet. The UK reference information explains the products cited here. A receiving pharmacy needs the offered presentation’s own documentation and local status when checking a supply enquiry.

Export product support

Need product, pack, and documentation details?

Global Medicines Export can support international B2B enquiries for product availability, strengths, pack information, quotation coordination, and shipment documentation review.

Common questions

Is finasteride 5 mg a stronger hair-loss treatment?

The UK reference products have different indications. The 1 mg hair-loss information states that a higher dose has not been shown to improve efficacy. A pack change needs a prescribing check.

Does stabilisation mean the treatment has failed to regrow hair?

Stabilisation and regrowth are different outcomes. Slower further thinning may still be a benefit. Compare progress with the starting appearance and the agreed treatment goal.

How long should I wait to judge hair response?

The cited UK 1 mg information generally expects three to six months before evidence of stabilisation. Safety symptoms require earlier action.

Will the benefit remain if I stop?

The UK 1 mg reference describes reversal of benefit after stopping, returning to baseline within nine to twelve months.

Can I double the next tablet if I miss one?

The UK 1 mg leaflet says not to double a dose. Follow the missed-dose directions for your exact product.

Can finasteride change a PSA result even if it was prescribed for hair?

Yes. Tell the clinician about finasteride use before PSA testing, including the strength and starting date, so the result can be interpreted appropriately.

Do vitamins replace a hair-loss assessment?

An assessment can identify whether there is a deficiency, another scalp condition or several contributing causes. The appropriate treatment follows those findings.

What should I do about a new sexual or mood change?

Report it promptly. The MHRA gives specific stop-and-contact advice for depression or suicidal thoughts during 1 mg treatment and prompt-contact advice during 5 mg treatment.

Important medical note

This article is for general educational information only. It is not medical advice, diagnosis, or a treatment plan. Medicines should be used only under the guidance of a qualified healthcare professional. Product availability, export documentation, and quotation support do not imply that a medicine is appropriate for any individual patient.

References